Dr. Hevia has always maintained a strong affinity to academic medicine.
He is always researching and studying the latest ingredients in skin care.
Procedures that are challenging for the inexperienced are simple and remarkably effective in the hands of a true professional such as Dr. Hevia. In a career spanning two decades, he has spent years honing his skills and developing his expertise with facial-care fillers, injectables, as well as with other related services and products.
Dr. Hevia has not only proven their effectiveness through in-depth research, he has often conducted – on behalf of universities or product-developers – the very rigorous and independent clinical trials which proved a given treatment’s effectiveness. As a result, his patients receive a well-rounded approach to their overall appearance and consistently satisfying appearances.
As investigator for numerous studies over the past two decades, Dr. Hevia sets the standard for innovative trends in the anti-aging and rejuvenation markets – both with procedural products and skin care. He has concluded that “anti-aging” is hardly the proper description – he prefers “refreshing, rejuvenating and restoring” – to bring out, for each patient, her natural beauty.
Dr. Hevia is well respected among pharmaceutical companies for his willingness to participate in clinical trials – they know that he consistently looks for better ways to approach his specialty, including better products and services.
As a result, he bypasses the media hype and prescribes products and procedures that are best suited to his patients’ needs.
CLINICAL STUDIES: DR. HEVIA SERVED AS INVESTIGATOR FOR THE FOLLOWING STUDIES:
- A DOUBLE-BLIND STUDY COMPARING THE EFFICACY OF A TOPICAL CREAM 1% VEHICLE IN THE TREATMENT OF ROSACEA
- A COMPARATIVE STUDY OF THE COSMETIC CHARACTERISTICS OF PSORCON CREAM vs. GENERIC FLUOCINONIDE 0.05%, DESOXIMETASONE 0.05%, AND CLOBETASOL PROPIONATA CREAM 0.05%
- AN OPEN-LABEL, MULTICENTER TRIAL TO EVALUATE THE SAFETY AND EFFECTIVENESS OF VARIOUS TREATMENT DURATIONS OF TERBINAFINE IN PATIENTS WITH ONYCHOMYCOSIS IN THE TOENAILS
- AN OPEN-LABEL NON-CONTROLLED STUDY TO ASSESS THE EFFICACY AND PATIENT ACCEPTANCE OF A TOPICAL CREAM MONOTHERAPY, CONCOMITANT THERAPY AND MAINTENANCE THERAPY IN THE TREATMENT OF ACNE VULGARIS
- A DOUBLE-BLIND, BILATERAL COMPARISON STUDY COMPARING THE EFFICACY OF 12% GLYCOLIC ACID CREAM vs. VITAMIN C SOLUTION IN THE TREATMENT OF PHOTOAGING
- A DOUBLE-BLIND, BILATERAL COMPARISON STUDY COMPARING THE EFFICACY OF 2 GLYCOLIC ACID BASE PRODUCTS IN THE TREATMENT OF PHOTOAGING
- A PROSPECTIVE, RANDOMIZED, COMPARATIVE, MULTICENTER STUDY OF SENSITIZATION TO RESTYLANE AND PERLANE AND INCLUDING AN ACUTE SAFETY PROFILE ASSESSMENT. JUNE 2005
- A PROSPECTIVE, OPEN LABEL, RANDOMIZED, PARALLEL GROUP, DOSE FINDING STUDY OF BOTULINUM TOXIN TYPE A FOR THE TREATMENT OF MODERATE TO SEVERE PLATYSMAL BANDS. AUGUST 2005
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF RELOXIN IN THE TREATMENT OF GLABELLAR LINES. OCTOBER 2005
- A RANDOMIZED, MULTI-CENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF EVOLENCE (DERMICOL P35) VERSUS RESTYLANE FOR THE CORRECTION OF THE SOFT TISSUE CONTOUR DEFICIENCIES. OCTOBER 2005
- A RANDOMIZED, EVALUATOR-BLIND, MULTI-CENTER, COMPARISON OF THE EFFICACY AND PERSISTENCE OF CORRECTION OF NASOLABIAL FOLDS WITH RESTYLANE USING TWO DIFFERENT RE-TREATMENT SCHEDULES. NOVEMBER 2005
- A DOUBLE BLIND DOSE COMPARISON OF THE SAFETY AND EFFICACY OF BOTOX IN THE TREATMENT OF FEMALE SUBJECTS WITH MODERATE OR SEVERE GLABELLAR RHYTIDS. APRIL 2006
- A PHASE III MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CONFIRMATORY STUDY OF THE EFFICACY AND SAFETY OF ISOLAGEN THERAPY IN THE TREATMENT OF NASOLABIAL FOLD CREASES. APRIL 2006
- CLINICAL RESEARCH STUDY TO HISTOLOGICALLY EVALUATE THE PERSISTENCE AND BIOCOMPATIBILITY CHANGES OF FOUR DIFFERENT TYPES OF FILLER MATERIALS ON HUMAN SUBJECTS. APRIL 2006
- PROSPECTIVE CLINICAL RESEARCH TO DETERMINE THE EFFECT OF TITAN LIGHT BASED DEVICE ON RESTYLANE DERMAL FILLER. OCTOBER 2006
- A DOUBLE MASKED, RANDOMIZED, MULTICENTER, 2-ARM PARALLEL STUDY COMPARING THE SAFETY AND EFFECTIVENESS OF AQUAMID AND RESTYLANE FOR THE AESTHETIC TREATMENT OF NASOLABIAL FOLDS. DECEMBER 2006
- A PHASE III, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOUBLE-BLIND STUDY OF THE SAFETY AND DURATION OF EFFICACY OF RELOXIN (BOTULINUM TYPE A TOXIN) IN CORRECTION OF MODERATE TO SEVERE GLABELLAR LINES (AND INCLUDING A SUB-STUDY TO DETECT ANY TREATMENT RELATED QT INTERVAL CHANGES. JANUARY 2007
- A MULTICENTER, OPEN-LABEL FEASIBILITY STUDY OF THE SAFETY AND EFFECTIVENESS OF JUVÉDERM ULTRA INJECTABLE GEL IN SUBJECTS WHO DESIRE LIP ENHANCEMENT. AUGUST 2007
- IT-A-008: A PHASE III DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF ISOLAGEN THERAPY IN THE TREATMENT OF MODERATE TO SEVERE FACIAL ACNE SCARRING. NOVEMBER 2007
- A PHASE 3, MULTI-CENTER TRIAL TO DEMOSTRATE THE SAFETY AND EFFICACY OF REPEAT TREATMENT OF GLABELLAR RHYTIDES (“FROWN LINES”). PT-03B DECEMBER 2007
- ARTES MEDICAL PROTOCOL #521-01: PROTOCOL FOR THE POST-APPROVAL STUDY OF ARTEFILL® FOR CORRECTION OF NASOLABIAL FOLDS. JANUARY 2008
- A PHASE 3, MULTICENTER, LONG TERM, REPEAT TREATMENT, OPEN LABEL, SINGLE ARM TRIAL TO DEMONSTRATE THE SAFETY OF REPEAT TREATMENT OF PURTOX FOR THE TREATMENT OF GLABELLAR RHYTIDS (“FROWN LINES”). PT03C. FEBRUARY 2008